EU/3/14/1348: Orphan designation for the treatment of glioma

Recombinant human bone morphogenetic protein 4

Overview

On 15 October 2014, orphan designation (EU/3/14/1348) was granted by the European Commission to Stemgen S.p.A., Italy, for recombinant human bone morphogenetic protein 4 for the treatment of glioma.

The sponsor’s address was updated in November 2020.

Key facts

Active substance
Recombinant human bone morphogenetic protein 4
Intended use
Treatment of glioma
Orphan designation status
Positive
EU designation number
EU/3/14/1348
Date of designation
15/10/2014
Sponsor

STEMGEN S.p.A.
Viale Bianca Maria 25
20122 Milano
Italy
Tel: + 39 348 1535 793
E-mail: zaccarini@stemgen.net

 

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating